The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
ORGANIZATION
JGA Bitterly Reprimands Kobayashi Kako for Application Document Fabrication
The Japan Generic Medicines Association (JGA) issued a statement on April 16 in the wake of a report on the latest revelation of Kobayashi Kako’s misconduct in fabricating application dossiers, saying, “The JGA deeply regrets to say it is an…
To read the full story
Related Article
- Kobayashi Kako Submits Biz Improvement Plan Over Fudged Drug Filings
May 31, 2021
- Biz Improvement Order Issued to 3 Codevelopers over Kobayashi Kako’s Fudged Data
May 24, 2021
- MHLW Revokes Approval for 12 Kobayashi Kako Products, Imposes Biz Improvement Order
April 30, 2021
- Kobayashi Kako Starts Recalling Products Subject to Approval Revocation
April 22, 2021
- Kobayashi Kako Chief Sorry for Fake Application Documents; Third-Party Report Reveals New Problems
April 19, 2021
- MHLW to Revoke Approval of 12 Kobayashi Kako Products as Documents Fabricated
April 19, 2021
- Kobayashi Kako Expelled from JGA over Drug Mix-Up
February 10, 2021
ORGANIZATION
- JGA to Create “Stable Supply Network” Membership to Expand Ramp-Up Scheme
December 18, 2025
- Pharma Groups Reiterate “No” to Broader CEA Use, Huge-Seller and Spillover Rules: Joint Statement
December 17, 2025
- Japan Medical Societies Recommend RSV Vaccination for Older Adults
December 15, 2025
- Labor Union Group Submits Request, Urges Drug Pricing Overhaul amid Inflation
December 3, 2025
- Wholesalers Urge Caution on Debating 2% Buffer without Bigger Reform Picture
November 28, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…